These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 18484778)

  • 41. Impact of glass corrosion on drug substance stability.
    Watkins MA; Iacocca RG; Shelbourn TL; Dong X; Stobba-Wiley C
    J Pharm Sci; 2014 Aug; 103(8):2456-63. PubMed ID: 24989460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Solutions to stabilisation issues.
    Lodhi M; Reed P
    Med Device Technol; 2005 May; 16(4):18-9, 21. PubMed ID: 15941193
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lyophilization closures for protein based drugs.
    DeGrazio F; Flynn K
    J Parenter Sci Technol; 1992; 46(2):54-61. PubMed ID: 1588459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Predicting drug hydrolysis based on moisture uptake in various packaging designs.
    Naversnik K; Bohanec S
    Eur J Pharm Sci; 2008 Dec; 35(5):447-56. PubMed ID: 18940251
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Predicting solution aggregation rates for therapeutic proteins: approaches and challenges.
    Roberts CJ; Das TK; Sahin E
    Int J Pharm; 2011 Oct; 418(2):318-33. PubMed ID: 21497188
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Thermal behavior and stability of biodegradable spray-dried microparticles containing triamcinolone.
    da Silva AA; de Matos JR; Formariz TP; Rossanezi G; Scarpa MV; do Egito ES; de Oliveira AG
    Int J Pharm; 2009 Feb; 368(1-2):45-55. PubMed ID: 18992313
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity of therapeutic proteins. Part 2: impact of container closures.
    Sharma B
    Biotechnol Adv; 2007; 25(3):318-24. PubMed ID: 17337336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Formulation for optimal safety and effectiveness.
    Schlichting DA
    Am J Pharm Sci Support Public Health; 1970; 142(1):16-22. PubMed ID: 5535904
    [No Abstract]   [Full Text] [Related]  

  • 49. [Pharmacy for physicians. Drug stability during storage and usage].
    Lundgren P
    Lakartidningen; 1972 Oct; 69():Suppl 3:36-40. PubMed ID: 4643062
    [No Abstract]   [Full Text] [Related]  

  • 50. Application of Formulation Principles to Stability Issues Encountered During Processing, Manufacturing, and Storage of Drug Substance and Drug Product Protein Therapeutics.
    Vitharana S; Stillahn JM; Katayama DS; Henry CS; Manning MC
    J Pharm Sci; 2023 Nov; 112(11):2724-2751. PubMed ID: 37572779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Conformational and bioactivity analysis of insulin: freeze-drying TBA/water co-solvent system in the presence of surfactant and sugar.
    Zhang Y; Deng Y; Wang X; Xu J; Li Z
    Int J Pharm; 2009 Apr; 371(1-2):71-81. PubMed ID: 19136051
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Risks in the delivery of drugs from the point of manufacture to the patient. I. Risks in manufacturing and compounding].
    Samková M; Solich J
    Cesk Farm; 1981 Dec; 30(10):349-54. PubMed ID: 7332939
    [No Abstract]   [Full Text] [Related]  

  • 53. Filling Unit Operation for Biological Drug Products: Challenges and Considerations.
    Adler M; Allmendinger A
    J Pharm Sci; 2024 Feb; 113(2):332-344. PubMed ID: 37992868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sub-visible particle quantitation in protein therapeutics.
    Cao S; Jiao N; Jiang Y; Mire-Sluis A; Narhi LO
    Pharmeur Bio Sci Notes; 2009 Oct; 2009(1):73-9. PubMed ID: 20144454
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of freeze-thawing on the long-term stability of calcium levofolinate in 5% dextrose stored on polyolefin infusion bags.
    Lebitasy M; Hecq JD; Athanassopoulos A; Vanbeckbergen D; Jamart J; Galanti L
    J Clin Pharm Ther; 2009 Aug; 34(4):423-8. PubMed ID: 19583675
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug product Formulation and Fill/Finish Manufacturing Process Considerations for AAV-Based Genomic Medicines.
    Som M; Gikanga B; Kanapuram V; Yadav S
    J Pharm Sci; 2024 Jul; 113(7):1711-1725. PubMed ID: 38570073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Challenges and solutions to manufacturing of low viscosity, ultra-high concentration IgG1 drug products: From late downstream process to final fill finish processing.
    Deokar VD; Sharma A; Subrahmanyam VM
    PDA J Pharm Sci Technol; 2024 Jun; ():. PubMed ID: 38942482
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Errors discovered in a manufacturing program.
    Das Gupta V
    Am J Hosp Pharm; 1973 Feb; 30(2):112. PubMed ID: 4690464
    [No Abstract]   [Full Text] [Related]  

  • 59. High-Voltage Leak Detection of a Parenteral Proteinaceous Solution Product Packaged in Form-Fill-Seal Plastic Laminate Bags. Part 3. Chemical Stability and Visual Appearance of a Protein-Based Aqueous Solution for Injection as a Function of HVLD Exposure.
    Rasmussen M; Damgaard R; Buus P; Guazzo DM
    PDA J Pharm Sci Technol; 2013; 67(6):664-9. PubMed ID: 24265306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Time- and temperature-dependent stability of growth factor peptides in human autologous serum eye drops.
    Bradley JC; Simoni J; Bradley RH; McCartney DL; Brown SM
    Cornea; 2009 Feb; 28(2):200-5. PubMed ID: 19158565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.